Engaging Cooperative Sites for Trial Acceleration, Trust, Innovation, and Capability (ECSTATIC)
与试验加速、信任、创新和能力合作站点合作 (ECSTATIC)
基本信息
- 批准号:10650682
- 负责人:
- 金额:$ 516.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-06-29 至 2028-04-30
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAdoptedAdoptionAgreementBiometryBudgetsBusinessesClinicalClinical ResearchClinical TrialsClinical Trials Data Monitoring CommitteesClinical Trials NetworkCollaborationsCompensationComplexContractsDataData CollectionData Coordinating CenterDiseaseDoctor of PhilosophyElasticityElectronic Health RecordElectronicsEnsureEpidemiologyFundingGrowthHealthHistorically Black Colleges and UniversitiesHumanImageInfrastructureInstitutionInstitutional Review BoardsLearningMethodologyMethodsMonitorMulti-Institutional Clinical TrialParticipantPhenotypePopulationProceduresProcessProductivityReadinessRecording of previous eventsReportingReproducibilityResearchResearch DesignResourcesRiskRuralSeasonsServicesShapesSiteStructureSystemTestingTimeTouch sensationTrainingTrustWorkbiobankclinical research sitecohortcommunity engagementcostdata managementdata standardselectronic consenthealth care deliveryhealth equityimprovedinnovationinterestmeetingsmulti-site trialnovelpractice-based research networkprogramsrandomized, clinical trialsrecruitsupport toolstooltrial designvirtual
项目摘要
Clinical research comes in many different shapes and sizes, and a robust network must accommodate all trial
types. No single organization can do this work alone. We have a deep commitment to both trial innovation
and collective network capacity within and beyond the CTSA Consortium and have a lengthy history of
supporting this approach. We have demonstrated an exceptional ability to collaboratively innovate and share
tools supporting clinical research coordination, including: global data management, mobile data collection,
recruitment, Electronic Health Record (EHR) research, single IRB coordination, contracting, community
engagement, returning value to participants, eConsent, virtual/remote participation in studies, and EHR
integration with REDCap. We will leverage and expand upon these programs as we are Engaging Cooperative
Sites for Trial Acceleration, Trust, Innovation, and Capability (ECSTATIC). We will establish a distributed
alliance of 6 CTSA-aligned coordinating centers to add elastic capacity and broaden expertise to the TIN’s
CCC/DCC infrastructure. Our alliance has 14 expert trialists that can inform the use of integrated approaches
for more efficient clinical research. Additionally, we will partner with the well-established Biostatistics,
Epidemiology, and Research Design (BERD) group and health equity experts to ensure every study has
access to needed expertise starting from study design through analysis. We will broaden the types of
organizations that can readily participate in clinical research across the U.S., including Historically Black
Colleges and Universities (HBCUs), to reach the populations most in need of support. Based on our novel
structure, merging teams from six different coordinating center groups, our TIC’s capacity is both scalable
and matched by expertise to intentionally accommodate all study design types. Led by Gordon Bernard,
MD, Wesley Self, MD, and Christopher Lindsell, PhD, each seasoned in leading and collaborating with
multisite clinical trial networks, ECSTATIC will embrace and draw on diverse expertise to build, test, and share
new resources that will enhance and accelerate rigorous, reproducible research for all CTSAs, to more rapidly
improve human health. Our Specific Aims are to: 1) demonstrate and disseminate novel integrated
approaches for more efficient clinical research including EHR-embedded, remote no-touch, and platform
trials, aligning with study needs; 2) expand and enrich clinical trial capability by increasing potential
participating site Expression of Interest (EOI) reach and readiness support (HBCUs and rural Practice-Based
Research Networks), better process integration with CTSAs, preparing study teams, and broader expert
engagement; 3) innovate clinical trial methodology by creating, evaluating, and disseminating new methods
for risk monitoring, AE reporting, direct EHR to REDCap data capture, and data standards to all CTSAs; and
4) provide a distributed alliance of clinical and data coordinating centers with extensive and diverse expertise
to offer support tailored for trial design, population, and condition.
临床研究有多种不同的形式和规模,强大的网络必须适应所有试验
没有任何一个组织可以单独完成这项工作,我们对这两种试验创新都有坚定的承诺。
CTSA 联盟内部和外部的集体网络容量,并且具有悠久的历史
我们展示了协作创新和共享的卓越能力。
支持临床研究协调的工具,包括:全球数据管理、移动数据收集、
招聘、电子健康记录 (EHR) 研究、单一 IRB 协调、承包、社区
参与、向参与者返还价值、电子同意、虚拟/远程参与研究以及 EHR
我们将在参与合作时利用并扩展这些计划。
我们将建立一个分布式试验加速、信任、创新和能力站点(ECSTATIC)。
由 6 个 CTSA 协调中心组成的联盟,旨在为 TIN 增加弹性能力并拓宽专业知识
CCC/DCC 基础设施我们的联盟拥有 14 名专家试验员,可以为综合方法的使用提供信息。
此外,我们将与成熟的生物统计学合作,
流行病学和研究设计 (BERD) 小组和健康公平专家确保每项研究都符合
从研究设计到分析,获取所需的专业知识。
可以轻松参与美国各地临床研究的组织,包括 Historically Black
学院和大学 (HBCU),为最需要支持的人群提供服务 根据我们的小说。
结构,合并来自六个不同协调中心组的团队,我们的TIC的能力是可扩展的
并配备专业知识,有意适应由戈登·伯纳德 (Gordon Bernard) 领导的所有研究设计类型,
医学博士、Wesley Self 医学博士和 Christopher Lindsell 博士,每个人都具有领导和合作的经验
多站点临床试验网络,ECSTATIC 将拥抱并利用不同的专业知识来构建、测试和共享
新资源将增强和加速所有 CTSA 的严格、可重复的研究,以更快地实现
改善人类健康。我们的具体目标是:1)展示和传播新型综合疗法。
更高效临床研究的方法,包括嵌入式 EHR、远程非接触式和平台
试验,与研究需求保持一致;2)通过增加潜力来扩大和丰富临床试验能力
参与地点意向书 (EOI) 覆盖范围和准备支持(HBCU 和农村基于实践的
研究网络)、与 CTSA 更好的流程集成、准备研究团队和更广泛的专家
3)通过创建、评估和传播新方法来创新临床试验方法
用于风险监控、AE 报告、直接 EHR 到 REDCap 数据采集以及所有 CTSA 的数据标准;
4) 提供具有广泛和多样化专业知识的临床和数据协调中心的分布式联盟
提供针对试验设计、人群和条件量身定制的支持。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gordon R Bernard其他文献
Gordon R Bernard的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gordon R Bernard', 18)}}的其他基金
ComPASS Collective for Community Engagement (C3E)
ComPASS 社区参与集体 (C3E)
- 批准号:
10903370 - 财政年份:2023
- 资助金额:
$ 516.98万 - 项目类别:
Coordination for ARDS, Pneumonia, and Sepsis supporting Training, Organization and Network Efficiency (CAPSTONE)
协调 ARDS、肺炎和败血症支持培训、组织和网络效率 (CAPSTONE)
- 批准号:
10647455 - 财政年份:2023
- 资助金额:
$ 516.98万 - 项目类别:
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma
胰高血糖素样肽 1 受体激动剂治疗成人肥胖相关症状性哮喘
- 批准号:
10398799 - 财政年份:2021
- 资助金额:
$ 516.98万 - 项目类别:
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma
胰高血糖素样肽 1 受体激动剂治疗成人肥胖相关症状性哮喘
- 批准号:
10084583 - 财政年份:2021
- 资助金额:
$ 516.98万 - 项目类别:
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma
胰高血糖素样肽 1 受体激动剂治疗成人肥胖相关症状性哮喘
- 批准号:
10609049 - 财政年份:2021
- 资助金额:
$ 516.98万 - 项目类别:
Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasma
范德比尔特临床和转化研究所 (VICTR) - 识别 SARS-CoV-2 恢复期血浆中功能免疫的相关性
- 批准号:
10254565 - 财政年份:2020
- 资助金额:
$ 516.98万 - 项目类别:
Vanderbilt Institute for Clinical and Translational Research (VICTR)
范德比尔特临床与转化研究所 (VICTR)
- 批准号:
10170009 - 财政年份:2020
- 资助金额:
$ 516.98万 - 项目类别:
Vanderbilt Institute for Clinical and Translational Research (VICTR)
范德比尔特临床与转化研究所 (VICTR)
- 批准号:
9490464 - 财政年份:2017
- 资助金额:
$ 516.98万 - 项目类别:
Vanderbilt Institute for Clinical and Translational Research (VICTR)
范德比尔特临床与转化研究所 (VICTR)
- 批准号:
9414517 - 财政年份:2017
- 资助金额:
$ 516.98万 - 项目类别:
Passive Immunity Trial for Our Neighbors (PassITON): A randomized, placebo-controlled multi-site trial of anti-SARS-CoV-2 convalescent plasma to treat hospitalized adults with COVID-19
为我们的邻居进行的被动免疫试验 (PassITON):一项随机、安慰剂对照的多中心抗 SARS-CoV-2 恢复期血浆试验,用于治疗患有 COVID-19 的住院成人
- 批准号:
10218949 - 财政年份:2017
- 资助金额:
$ 516.98万 - 项目类别:
相似国自然基金
锶银离子缓释钛表面通过线粒体自噬调控NLRP3炎症小体活化水平促进骨整合的机制研究
- 批准号:82301139
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
万寿菊黄酮通过MAPK/Nrf2-ARE通路缓解肉鸡肠道氧化应激损伤的作用机制
- 批准号:32302787
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
肠道菌群及其代谢产物通过mRNA m6A修饰调控猪肉品质的机制研究
- 批准号:32330098
- 批准年份:2023
- 资助金额:220 万元
- 项目类别:重点项目
PUFAs通过SREBPs提高凡纳滨对虾低盐适应能力的机制研究
- 批准号:32303021
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
EGLN3羟化酶通过调控巨噬细胞重编程促进肺癌细胞EMT及转移的机制研究
- 批准号:82373030
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
The University of Miami AIDS Research Center on Mental Health and HIV/AIDS - Center for HIV & Research in Mental Health (CHARM)Research Core - EIS
迈阿密大学艾滋病心理健康和艾滋病毒/艾滋病研究中心 - Center for HIV
- 批准号:
10686546 - 财政年份:2023
- 资助金额:
$ 516.98万 - 项目类别:
Extensible Open Source Zero-Footprint Web Viewer for Cancer Imaging Research
用于癌症成像研究的可扩展开源零足迹 Web 查看器
- 批准号:
10644112 - 财政年份:2023
- 资助金额:
$ 516.98万 - 项目类别:
Accelerating genomic analysis for time critical clinical applications
加速时间紧迫的临床应用的基因组分析
- 批准号:
10593480 - 财政年份:2023
- 资助金额:
$ 516.98万 - 项目类别:
Augmenting Pharmacogenetics with Multi-Omics Data and Techniques to Predict Adverse Drug Reactions to NSAIDs
利用多组学数据和技术增强药物遗传学,预测 NSAID 的药物不良反应
- 批准号:
10748642 - 财政年份:2023
- 资助金额:
$ 516.98万 - 项目类别: